BioCryst Pharmaceuticals, Inc. (BCRX) News
Filter BCRX News Items
BCRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCRX News Highlights
- For BCRX, its 30 day story count is now at 28.
- Over the past 23 days, the trend for BCRX's stories per day has been choppy and unclear. It has oscillated between 1 and 11.
- HAE, MSCI and CTLT are the most mentioned tickers in articles about BCRX.
Latest BCRX News From Around the Web
Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.
BioCryst posts long-term data for hereditary angioedema therapyOn Thursday, BioCryst Pharmaceuticals (NASDAQ:BCRX) highlighted the long-term potential of its oral hereditary angioedema (HAE) therapy Orladeyo after the release of the latest data from its APeX-2 trial designed to evaluate the once-daily drug as a prophylactic treatment. 96-week data of the 121-patient trial were previously disclosed in July 2021,... |
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96 weeks of treatment —RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of |
BioCryst Pharmaceuticals Non-GAAP EPS of -$0.40 misses by $0.11, revenue of $47.2M misses by $3.28MBioCryst Pharmaceuticals press release (NASDAQ:BCRX): Q4 Non-GAAP EPS of -$0.40 misses by $0.11. Revenue of $47.2M (+1080.0% Y/Y) misses by $3.28M. ORLADEYO net revenue in the fourth quarter of 2021 was $46.2M. Cash, cash equivalents, restricted cash and investments totaled $517.8 million as of December 31, 2021, compared to $302.6... |
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call TranscriptBioCryst Pharmaceuticals, Inc. (BCRX) Q4 2021 Results Conference Call February 23, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Dr. Helen Thackray - Chief R&D Officer... |
Recap: BioCryst Pharmaceuticals Q4 EarningsBioCryst Pharmaceuticals (NASDAQ: BCRX ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings BioCryst Pharmaceuticals missed estimated earnings by 33.33%, reporting an EPS of $-0.4 versus Full story available on Benzinga.com |
BioCryst slips after lower-than-expected Q4 2021 resultsImilian/iStock via Getty Images The commercial-stage biotech company BioCryst Pharmaceuticals (NASDAQ:BCRX) is trading ~7% lower in the pre-market on Wednesday after the companys Q4 2021 |
Why BioCryst Pharmaceuticals Stock Slid TodayThe biotech''s immediate future doesn''t look profitable. |
BioCryst Pharmaceuticals (BCRX) Q4 2021 Earnings Call TranscriptBCRX earnings call for the period ending December 31, 2021. |
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue EstimatesBioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients — RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a corporate update. |